Literature DB >> 7880726

Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.

R J Gilbertson1, A D Pearson, R H Perry, E Jaros, P J Kelly.   

Abstract

The expression and prognostic significance of the c-erbB-2 oncogene product was studied in 55 cases of childhood medulloblastoma. Forty-six of the 55 tumours (83.6%) expressed the c-erbB-2 product. The percentage of tumour cells expressing the c-erbB-2 product proved to be a significant indicator of patient outcome when analysed as both a categorical and a continuous variable. As a categorical variable, patients with more than 50% positive tumour cells had a significantly worse survival, with only 10% alive at 10 years vs 48% for those with less than 50% positive tumour cells (log rank P = 0.0049). To demonstrate that this observed prognostic significance was both independent and not a result of 'data-driven' categorisation, it was also entered into the Cox model as a continuous variable. Prognostic significance was retained in P = 0.038.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7880726      PMCID: PMC2033658          DOI: 10.1038/bjc.1995.96

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line.

Authors:  S Fukushige; K Matsubara; M Yoshida; M Sasaki; T Suzuki; K Semba; K Toyoshima; T Yamamoto
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

2.  Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

Authors:  R Peto; M C Pike
Journal:  Biometrics       Date:  1973-09       Impact factor: 2.571

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Expression of the c-erbB-2 protein in normal and transformed cells.

Authors:  W J Gullick; M S Berger; P L Bennett; J B Rothbard; M D Waterfield
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

5.  Medulloblastoma and other primary malignant neuroectodermal tumors of the CNS. The effect of patients' age and extent of disease on prognosis.

Authors:  J C Allen; F Epstein
Journal:  J Neurosurg       Date:  1982-10       Impact factor: 5.115

6.  Radiation treatment for medulloblastoma. A 21-year review.

Authors:  M P Berry; R D Jenkin; C W Keen; B D Nair; W J Simpson
Journal:  J Neurosurg       Date:  1981-07       Impact factor: 5.115

7.  A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation.

Authors:  A J Caputy; D C McCullough; H J Manz; K Patterson; M K Hammock
Journal:  J Neurosurg       Date:  1987-01       Impact factor: 5.115

8.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

9.  Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management.

Authors:  G Kopelson; R M Linggood; G M Kleinman
Journal:  Cancer       Date:  1983-01-15       Impact factor: 6.860

10.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

View more
  19 in total

Review 1.  Pediatric surgical neuro-oncology: current best care practices and strategies.

Authors:  James T Rutka; John S Kuo
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 2.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 3.  Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.

Authors:  D M Ashley; S K Batra; D D Bigner
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

Review 4.  Recent advances in embryonal tumours of the central nervous system.

Authors:  Chitra Sarkar; Prabal Deb; Mehar Chand Sharma
Journal:  Childs Nerv Syst       Date:  2005-01-29       Impact factor: 1.475

5.  Molecular biology of medulloblastoma: will it ever make a difference to clinical management?

Authors:  Richard J Gilbertson; Amar Gajjar
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

6.  Impact of molecular biology studies on the understanding of brain tumors in childhood.

Authors:  Amulya A Nageswara Rao; Roger J Packer
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 7.  Aggressive infantile embryonal tumors.

Authors:  Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Authors:  Nabil Ahmed; Vita S Salsman; Eric Yvon; Chrystal U Louis; Laszlo Perlaky; Winfried S Wels; Meghan K Dishop; Eugenie E Kleinerman; Martin Pule; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

Review 9.  Cellular immunotherapy for pediatric solid tumors.

Authors:  Meenakshi Hegde; Alexander J Moll; Tiara T Byrd; Chrystal U Louis; Nabil Ahmed
Journal:  Cytotherapy       Date:  2014-07-28       Impact factor: 5.414

10.  HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.

Authors:  Nabil Ahmed; Vita S Salsman; Yvonne Kew; Donald Shaffer; Suzanne Powell; Yi J Zhang; Robert G Grossman; Helen E Heslop; Stephen Gottschalk
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.